Table 1 Descriptive characteristics of examined cohorts
Gender n (%) | |
F | 15/30 (50 %) |
M | 15/30 (50 %) |
Age, median (IQR) | 33 (29; 44) |
Diagnosis n (%) | |
CD | 18/30 (60 %) |
L1 | 8/18 (44 %) |
L2 | 2/18 (12 %) |
L3 | 8/18 (44 %) |
B1 | 6/18 (33 %) |
B2 | 7/18 (39 %) |
B2 + 3 | 4/18 (22 %) |
B3 | 1/18 (6 %) |
UC | 12/30 (40 %) |
E2 | 4/12 (33 %) |
E3 | 8/12 (67 %) |
Concomitant treatment n (%) | |
Immunosuppressants | 11/30 (37 %) |
Corticosteroids | 16/30 (53 %) |
Mesalazine | 21/30 (70 %) |
Response to the IFX treatment n (%) | |
Responders | 20/30 (67 %) |
Responders with adverse events | 6/30 (20 %) |
Primary non-responders | 1/30 (3 %) |
Secondary non-responders | 3/30 (10 %) |